Accessibility StatementSkip Navigation Total revenues were $4.7 billion in the third quarter of 2025, compared with $2.9 billion in the third quarter of 2024, primarily due to net investment gains of $275 million this quarter compared to net investment losses of $1.4 billion in the third quarter of 2024. Net earnings were $1.6 billion, or $3.08 per diluted share, compared with net losses of $93 million, or losses of $0.17 per diluted share a year ago. Net earnings in the third quarter of 2025 included net i ...

Core Insights - Aflac Incorporated (AFL) is positioned for growth due to expanding sales in Japan and the U.S., a trusted brand, innovative products, strict underwriting discipline, and effective cost management [1][3][4] Sales Performance - Sales in Japan increased by 18.7% year-over-year in the first half of the year, reaching $236 million, driven by strong sales of Miraito and efforts to attract younger customers with Tsumitasu [3][9] - U.S. sales rose by 3.1% year-over-year to $649 million, with group life and disability products contributing significantly to this growth [3][9] Margin Analysis - The company anticipates pretax margins of 30-33% in Japan and 17-20% in the U.S. for 2025, with the U.S. segment achieving a 22.5% pretax margin in the second quarter due to cost-control measures [4][9] Business Resilience - Demand for supplemental insurance remains strong, as these products address coverage gaps rather than compete with traditional offerings, providing Aflac with a stable revenue stream less affected by economic fluctuations [5] Shareholder Value Initiatives - Aflac prioritized shareholder rewards, repurchasing 7.9 million shares worth $829 million in the second quarter and authorizing an additional 100 million shares for repurchase, totaling approximately 130.9 million shares remaining [6] - The company extended its dividend growth streak to 42 consecutive years in 2024, with total capital deployment reaching $2.4 billion in the first half of 2025 [6] Earnings Performance - Aflac's earnings have exceeded the Zacks Consensus Estimate in two of the last four quarters, with an average surprise of 6.6% [7] Industry Competitors - Competitors like AMERISAFE, Inc. and Globe Life Inc. are also active in the market, with AMERISAFE focusing on workers' compensation and maintaining a strong retention rate, while Globe Life benefits from steady premium income and underwriting margins [10][11]

Core Insights - Aflac Incorporated (AFL) has expanded its share repurchase program by adding 100 million shares to the existing 30.9 million, bringing the total buyback capacity to approximately 130.9 million shares, indicating management's confidence in the company's long-term prospects [1][8] - In Q2, Aflac repurchased 7.9 million shares for $829 million and declared a dividend of 58 cents per share, with a dividend yield of 2.24%, surpassing the industry average of 2.05% [2][8] - Aflac ended Q2 with $7 billion in cash and cash equivalents, an 11.8% increase from year-end 2024, and maintained a total debt-to-capital ratio of 24.7%, below the industry average [3] Financial Performance - Adjusted net investment income rose to $1 billion in Q2, with the U.S. segment's pre-tax profit margin improving to 21.6% from 21.1% in 2024 [3] - Aflac Japan reported an 18.7% year-over-year sales increase to $236 million in H1 2025, driven by sales momentum from Miraito and new product launches [4][8] Industry Context - Other insurers like Aon plc and Marsh & McLennan are also engaging in shareholder-friendly initiatives, including share repurchase programs and dividends [5] - Aon repurchased 0.7 million shares for approximately $250 million in Q2, while Marsh & McLennan bought back 1.4 million shares worth $300 million [6] Valuation and Estimates - Aflac shares have gained 2.2% year-to-date, slightly outperforming the industry growth of 2% [7] - The company trades at a forward price-to-earnings ratio of 14.91, above the industry average of 12.14, with a Zacks Consensus Estimate for 2025 earnings at $6.81 per share, reflecting a 5.6% decline from the previous year [10][11]

Core Insights - Aflac Incorporated reported a significant decline in total revenues and net earnings for the second quarter of 2025 compared to the same period in 2024, primarily due to net investment losses [2][3][7] Financial Performance - Total revenues for Q2 2025 were $4.2 billion, down 19.0% from $5.1 billion in Q2 2024 [2][27] - Net earnings fell to $599 million, or $1.11 per diluted share, a decrease of 65.9% from $1.8 billion, or $3.10 per diluted share, a year earlier [2][27] - Adjusted earnings for Q2 2025 were $957 million, down 7.5% from $1.0 billion in Q2 2024 [4][32] Investment Performance - The company experienced net investment losses of $421 million in Q2 2025, compared to net investment gains of $696 million in Q2 2024 [3][37] - Adjusted net investment income for Q2 2025 was $1.036 billion, a slight increase of 0.3% from $1.033 billion in Q2 2024 [38] Shareholder Equity - Shareholders' equity increased to $27.2 billion, or $50.86 per share, at June 30, 2025, compared to $26.0 billion, or $46.40 per share, at June 30, 2024 [6][39] - The annualized return on average shareholders' equity for Q2 2025 was 9.0% [6][40] Segment Performance - Aflac Japan's net earned premiums in yen decreased by 4.8% to ¥254.6 billion in Q2 2025, primarily due to internal cancer reinsurance transactions [9][10] - In dollar terms, Aflac U.S. net earned premiums increased by 3.4% to $1.5 billion in Q2 2025, reflecting improved sales and persistency [14][15] Sales and Growth - Total new annualized premium sales in Aflac Japan increased by 23.2% to ¥20.7 billion, or $143 million, in Q2 2025 [13] - Aflac U.S. sales increased by 2.7% in Q2 2025 to $340 million, benefiting from group life and disability products [16] Capital Management - The board declared a third-quarter dividend of $0.58 per share, payable on September 2, 2025 [19] - Aflac repurchased $829 million in shares during Q2 2025, with 30.9 million shares remaining authorized for repurchase [19][23]